• No questions for this search term

Which consortium or company is most economically successful for covid-19 vaccine development?

Back to ranking

Transactions by Scott Bugbee

Amounts in Credits
Timestamp Answer option Long (for) Short (against) Shares Price % P&L (in Credits)
Total 19,999.99 0.00 -0.01
2020/11/12 23:28:24   T BNT162b1: BioNTech, Pfizer 2,000.00 - 9,952.22 20.10 -2,000.00
2020/11/12 23:28:40   T AZD1222 (ChAdOx1 nCoV-19): Oxford University, AstraZeneca 2,000.00 - 10,121.04 19.76 -2,000.00
2020/11/12 23:28:47   T One of the 121 other vaccines in development 1,000.00 - 4,801.24 20.83 -1,000.00
2020/11/12 23:28:55   T mRNA-1273: Moderna, NIAID 2,000.00 - 9,167.24 21.82 -2,000.00
2020/11/12 23:29:20   T BNT162b1: BioNTech, Pfizer 1,103.67 - 5,428.16 20.33 -1,103.67
2020/11/12 23:29:43   T mRNA-1273: Moderna, NIAID -80.30 - -359.26 22.35 +80.30
2020/11/12 23:30:00   T mRNA-1273: Moderna, NIAID 1,893.67 - 8,204.21 23.08 -1,893.67
2020/11/12 23:30:40   T BNT162b1: BioNTech, Pfizer 82.96 - 405.89 20.44 -82.96
2024/05/16 02:14:51   M mRNA-1273: Moderna, NIAID 3,911.83 - 17,012.19 23.83 +3,911.83
2024/05/16 02:14:51   M AZD1222 (ChAdOx1 nCoV-19): Oxford University, AstraZeneca 2,042.14 - 10,121.04 19.35 +2,042.14
2024/05/16 02:14:51   M BNT162b1: BioNTech, Pfizer 3,025.30 - 15,786.27 20.47 +3,025.30
2024/05/16 02:14:51   M One of the 121 other vaccines in development 1,020.73 - 4,801.24 20.16 +1,020.73
O=Opening valuation, M=Market valuation, C=Closing valuation, T=Trade, R=Reversal, S=Settlement